# Mytide Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mytide-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.mytide.io
- Total disclosed funding: $6.6M
- Latest round: Series A (Dec 30, 2021)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2018 by co-founders Dale Thomas and Jason Norris, Mytide Therapeutics, Inc. operates as a peptide and biopolymer manufacturing and computational biology company for serious conditions, ranging from cancer to inflammatory disorders and infectious diseases. In March 2020, Mytide Therapeutics, Inc. raised USD 7 million in series A funding led by new investor Alloy Therapeutics, Inc., with participation from another new investor, Trog Hawley Capital. Returning investor Uncommon Denominator and the company's management also participated in the round. 

Mytide Therapeutics, Inc. offers automated peptide manufacturing technology, with analytics and machine learning, providing quoting, property calculator, order tracking, and a data analysis suite. Its Rapid Automated Computation, Coupling, Cleavage, and Chromatography Execution platform provides computational biology that enables molecule identification and selection. 

The company will use the series A funding to scale its AI-enabled Gen2 platform and to support manufacturing for peptide and peptide conjugate applications for therapeutic discovery and personal peptide vaccines (PPV).

## Funding rounds

- Series A, Dec 30, 2021, $6.6M — Uncommon Denominator, Alloy Therapeutics, Inc.

## Investors

- Uncommon Denominator (https://capitalatlas.ai/funds/uncommon-denominator) — Series A
- Alloy Therapeutics, Inc. — Series A